<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123318</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 03.02</org_study_id>
    <nct_id>NCT00123318</nct_id>
  </id_info>
  <brief_title>A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer</brief_title>
  <official_title>A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Royal Australian and New Zealand College of Radiologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans-Tasman Radiation Oncology Group (TROG)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the side-effects and effectiveness of a new type of
      chemoradiotherapy treatment for patients who have had surgery for stomach cancer. The
      treatment uses epirubicin, cisplatin, and 5-fluorouracil (ECF) chemotherapy together with
      radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been shown recently in a study conducted in the USA (INT0116) that postoperative,
      adjuvant chemoradiotherapy improves survival for patients with gastric cancer. This treatment
      is relatively new and there remains debate regarding the optimal chemotherapy regimen and the
      optimal method of radiotherapy delivery. This study will evaluate a new regimen of adjuvant
      chemoradiotherapy for gastric cancer that employs ECF chemotherapy as the systemic component
      given before and after concurrent chemoradiation with continuous infusional 5-fluorouracil.
      Patients receive one cycle of ECF, followed 28 days later by chemoradiotherapy to a radiation
      dose of 45 Gy in 25 fractions over 5 weeks, and then one month later two further cycles of
      ECF are given. All patients are treated using multiple-field conformal radiation techniques.

      The specific objectives of the study are:

        -  To detail the acute toxicity associated with this treatment.

        -  To determine the feasibility of the proposed concurrent chemoradiation regimen.

        -  To determine the feasibility of a standardized technique for radiation treatment
           planning and delivery.

      The study will help to develop a common approach to the adjuvant treatment of gastric cancer,
      which is required before initiating further clinical trials in gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients who develop grade 3 or grade 4 haematological and gastrointestinal acute toxicity</measure>
    <time_frame>Final analysis will be at 3 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of patients who complete the planned chemoradiation protocol</measure>
    <time_frame>Final analysis will be at 3 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of major radiotherapy protocol violations</measure>
    <time_frame>Final analysis will be at 3 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median survival and overall survival at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin</intervention_name>
    <description>50mg/m2 IV day 1</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Epirubicin Ebewe, Epirubicin Hydrochloride for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>60mg/m2 IV day 1</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cisplatin Ebewe, Cisplatin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line</description>
    <arm_group_label>1</arm_group_label>
    <other_name>DBL Fluoruracil Injection BP, Efudix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>45Gy 25 Fractions, 5 days/week for 5 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All of the following must apply:

          -  Histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction
             that is:

               1. completely resected with negative margins

               2. Stage T3,4 and/or N1,2 patients who have undergone a D2 nodal dissection can be
                  entered on the study at the discretion of the treating clinician.

          -  Age greater than or equal to 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2

          -  Adequate organ function defined as follows:

               -  Bone marrow: Haemoglobin greater than or equal to 90 g/L; Neutrophil count
                  greater than or equal to 1.5 x 10^9 /L; Platelet count greater than or equal to
                  100 x 10^9 /L

               -  Hepatic: Serum bilirubin less than or equal to 1.5 x ULN; AST and/or ALT less
                  than or equal to 3.0 x ULN;

               -  Renal: Serum creatinine less than or equal to 0.150 mmol/L, and calculated
                  creatinine clearance greater than or equal to 50mL/min.

          -  Adequate oral nutrition (intake greater than or equal to 1500 calories/day). This is
             to be assessed by a dietician prior to commencing treatment.

          -  Disease which can be radically treated to 45 Gy with standard fractionation.

          -  Patient able to be treated with infusional 5-fluorouracil (5-FU) and ECF chemotherapy.

          -  Written informed consent

        Exclusion Criteria:

        None of the following must apply:

          -  Evidence of metastatic disease.

          -  Prior chemotherapy or radiotherapy

          -  Patients with other significant underlying medical conditions that may be aggravated
             by the study treatment or are not controlled.

          -  Pregnant or lactating females or female patients of childbearing potential who have
             not been surgically sterilized or are without adequate contraceptive measures.

          -  Cardiac failure (relevant to the use of epirubicin):

               -  Patients with myocardial infarction within the last 6 months;

               -  Patients with New York Heart Association class III/IV congestive heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trevor Leong</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>1871</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Cancer Care Centre</name>
      <address>
        <city>Penrith</city>
        <state>New South Wales</state>
        <zip>2751</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2069</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater QRI</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Coast Cancer Centre</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Launceston General Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andrew Love Cancer Care Centre, Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://www.trog.com.au</url>
    <description>Click here for more information about this study on the TROG official website</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

